Remedey, a company specializing in the development and manufacturing of medical equipment, is conducting an IPO subscription for general investors over two days from July 1 to 2. As of the morning of Wednesday the 2nd, the equal allocation share count stands at 1.18, though it should be noted that it is still early in the day.

Remedey achieved strong subscription results during the institutional investor demand forecasting, with 2,246 institutions participating and recording a competition ratio of 1,146 to 1. Accordingly, the public offering price was finalized at 20,700 won, the upper end of the desired range, with KB Securities serving as the lead underwriter. The market is closely watching whether the robust institutional demand forecast and the determination of the offering price at the upper end will positively impact investor sentiment.

Remedey is a company that supplies medical imaging equipment, including medical X-ray devices, as well as related solutions. Based on low-dose and miniaturization technologies, the company is expanding its business primarily in the medical sector.

Meanwhile, some advise that a cautious approach is necessary for investment decisions, as newly listed stocks may experience increased price volatility following listing. Remedey is scheduled to list on the KOSDAQ market on July 13.

[This article was written with the assistance of AI. This article does not constitute investment advice, and the final judgment and responsibility for IPO investments lie with the investor.]